Evidence map›Paper›PMID 38169282›Full record

ArticleAntimicrobial agents and chemotherapy2024

The metabolic slowdown caused by the deletion of

Yingxing Li, Xiao Chen, Weili Zhang, Kefan Fang, Jingjing Tian, Fangyuan Li, Mingfei Han, Jingjing Huang, Tianshu Sun, Fan Bai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yingxing Li *Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-8984-9136
Xiao Chen *Biomedical Pioneering Innovation Centre (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
Weili ZhangCenter for Infectious Disease Research, School of Medicine, Tsinghua University, Beijing, China.
Kefan FangBiomedical Pioneering Innovation Centre (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
Jingjing TianBiomedical Engineering Facility of National Infrastructures for Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fangyuan LiClinical Biobank, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Mingfei HanNational Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China.
Jingjing HuangDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tianshu SunDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fan BaiBiomedical Pioneering Innovation Centre (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
Mei ChengDepartment of Clinical Laboratory, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yingchun XuDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-7126-9459

Funding

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2021-I2M-1-038MOST | National Natural Science Foundation of China (NSFC) 32000024MOST | National Natural Science Foundation of China (NSFC) 82002314Special Foundation for National Science and Technology Basic Research Program of China 2019FY101205
6 · The paper itself

Abstract

Entering a dormant state is a prevailing mechanism used by bacterial cells to transiently evade antibiotic attacks and become persisters. The dynamic progression of bacterial dormancy depths driven by protein aggregation has been found to be critical for antibiotic persistence in recent years. However, our current understanding of the endogenous genes that affects dormancy depth remains limited. Here, we discovered a novel role of phage shock protein A (

Indexed as

Anti-Bacterial AgentsProtein AggregatesAdenosine TriphosphateEscherichia coliGlucoseAdenosine TriphosphateAnti-Bacterial AgentsGlucoseProtein Aggregatesantibiotic persistencedormancy depthpersistersprotein aggregationpspAVBNC cells

Identifiers

PMID38169282
PMCPMC10848772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.